North America Psoriasis Treatment Market Future-Proof Strategies: Market Trends 2025-2033

Key Insights

The size of the North America Psoriasis Treatment Market was valued at USD 19.03 USD billion in 2023 and is projected to reach USD 36.38 USD billion by 2032, with an expected CAGR of 9.7% during the forecast period. Psoriasis is a chronic autoimmune skin condition characterized by the rapid buildup of skin cells, leading to scaling, inflammation, redness, and itching. Effective treatment for psoriasis focuses on managing symptoms and preventing flare-ups. Common approaches include topical treatments like corticosteroids, vitamin D analogs, and salicylic acid to reduce inflammation and scaling. Phototherapy, involving controlled exposure to ultraviolet (UV) light, is often recommended for moderate to severe cases. Systemic treatments, such as oral or injectable medications like methotrexate, cyclosporine, or biologics targeting specific immune pathways (e.g., TNF inhibitors, IL-17 or IL-23 inhibitors), are used for severe or treatment-resistant psoriasis. Lifestyle adjustments, including stress management, a balanced diet, and avoiding triggers like smoking or alcohol, can also help improve outcomes.

North America Psoriasis Treatment Market Trends

The North American psoriasis treatment market is characterized by dynamic shifts and evolving patient care philosophies. Key trends shaping the landscape include:

Driving Forces: What's Propelling the North America Psoriasis Treatment Market

Challenges and Restraints in North America Psoriasis Treatment Market

1. High Treatment Costs: The cost of psoriasis treatments, especially biologics, can be a barrier to access.
2. Treatment Resistance: Some patients experience resistance to available treatments, limiting therapeutic options.
3. Side Effects and Safety Concerns: Biologic therapies may be associated with potential side effects, requiring careful monitoring.
4. Lack of Universal Treatment Regimen: The optimal treatment for psoriasis varies between individuals, posing a challenge for healthcare providers.
5. Limited Access in Underserved Areas: Rural and low-income communities may have limited access to specialized psoriasis care.

Key Region or Country & Segment to Dominate the Market

Dominant Region: The United States is projected to maintain its lead in the North American psoriasis treatment market. This dominance is attributed to its extensive patient population, high reported prevalence of psoriasis, substantial investment in pharmaceutical R&D, sophisticated healthcare infrastructure, and robust adoption of cutting-edge therapies.

Dominant Segment: The biologics segment is expected to continue its stronghold and exhibit significant growth. Biologics, including monoclonal antibodies and fusion proteins, offer high efficacy for moderate to severe cases and are increasingly being prescribed due to their targeted mechanisms and favorable long-term safety profiles.

Emerging Segment: The oral medication segment is poised for substantial expansion. The development of new oral small molecules and the increasing acceptance of existing oral therapies are making them a preferred choice for many patients due to their convenience, ease of administration, and growing efficacy, presenting a strong alternative to injectables.

Growth Catalysts in North America Psoriasis Treatment Industry

1. Innovation in Drug Delivery Systems: Advancements in drug delivery systems, such as transdermal patches and nanoparticles, enhance medication absorption and effectiveness.
2. Growing Telehealth Adoption: Telehealth platforms facilitate remote patient consultations, medication management, and support group connections.
3. Personalized Medicine: Genetic testing and biomarkers help identify the most effective treatment for individual patients, optimizing outcomes.
4. Increased Focus on Patient Education: Patient education programs empower individuals to manage their psoriasis proactively and improve self-care practices.
5. Government Initiatives and Funding: Government support for research, awareness campaigns, and patient assistance programs fosters market growth.

North America Psoriasis Treatment Market Segmentation

• 1. Drug Class
  • 1.1. TNF Inhibitors
  • 1.2. Interleukins
  • 1.3. Others
• 2. Type
  • 2.1. Plaque Psoriasis
  • 2.2. Psoriatic Arthritis
  • 2.3. Others
• 3. Route of Administration
  • 3.1. Oral, Parenteral/Systemic, and Topical
    • 3.1.1. Branded and Generics
• 4. Distribution Channel
  • 4.1. Hospital Pharmacies
  • 4.2. Retail Pharmacies
  • 4.3. Online Pharmacies

Leading Players in the North America Psoriasis Treatment Market

• AbbVie, Inc. (U.S.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer, Inc. (U.S.)
• LEO Pharma A/S (Denmark)
• Merck & Co., Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Evelo Biosciences, Inc. (U.S.)

Significant Developments in North America Psoriasis Treatment Sector

January 2024: Johnson & Johnson Services, Inc. presented positive findings from a Phase 3b study of TREMFYA (guselkumab), highlighting its significant efficacy in treating severe scalp psoriasis, further expanding the therapeutic options for this challenging presentation of the disease.

October 2023: Pfizer, Inc. announced a major milestone with the U.S. FDA approval of ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira, enhancing patient access to a well-established treatment option for psoriasis at potentially lower costs.

July 2023: AbbVie, Inc. revealed compelling results from a Phase 4 head-to-head study of SKYRIZI (risankizumab) against Apremilast, demonstrating SKYRIZI's superior efficacy in managing plaque psoriasis, reinforcing its position as a leading biologic therapy.

December 2021: Amgen Inc. reported encouraging clinical outcomes from a pivotal Phase 3 study evaluating Otezla (apremilast) for moderate to severe plaque psoriasis, underscoring its continued relevance and efficacy in the treatment landscape.

July 2020: Johnson & Johnson Services, Inc. secured U.S. FDA approval for Stelara (ustekinumab) for the treatment of mild to moderate plaque psoriasis in pediatric patients aged 6-11 years, marking a significant step in extending effective psoriasis treatment to younger age groups.

Comprehensive Coverage North America Psoriasis Treatment Market Report

Market Segmentation:

• Market size and forecast by drug class, type, route of administration, and distribution channel
• Analysis of emerging and niche segments with high growth potential

Geographic Analysis:

• In-depth analysis of the North American market, with a focus on key countries like the United States, Canada, and Mexico
• Identification of growth opportunities in key regions and emerging markets

Competitive Landscape:

• Comprehensive profiles of major players in the market
• Analysis of market share, strategies, and competitive dynamics
• Insights into mergers, acquisitions, and partnerships shaping the industry

Industry Trends and Forecast:

• Analysis of industry trends, including advancements in drug development, regulatory changes, and market dynamics
• Forecast of market size and growth for the coming years
• Identification of key drivers and challenges impacting the industry

DROCT

The Detailed Report of North America Psoriasis Treatment Market includes:

• Executive Summary
• Market Dynamics
• Segmentation Analysis
• Competitive Landscape
• Geographic Analysis
• Industry Outlook and Forecast
• Appendix

Pricing Analysis

The report provides a comprehensive analysis of pricing trends in the North American psoriasis treatment market, including:

• Historical and current pricing data for different drug classes and brands
• Analysis of factors influencing pricing, such as research and development costs, manufacturing costs, and payer negotiations
• Forecast of future pricing trends

Import And Export Analysis

The report provides detailed insights into the import and export dynamics of the North American psoriasis treatment market, including:

• Analysis of import and export volumes, values, and trends
• Identification of major import and export markets
• Analysis of trade regulations and tariffs impacting the market

Patent/Trademark Analysis

The report provides a comprehensive analysis of patents and trademarks in the North American psoriasis treatment market, including:

• Analysis of key patents and trademarks held by major players
• Identification of patent expiration dates and potential generic competition
• Assessment of the impact of intellectual property on market dynamics